OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern	333
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters	94
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase	70
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes	65
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020	64
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice	52
An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral	52
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation	51
Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies	50
Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E	50
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents	50
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis	48
Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro	46
Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro	45
Burden of influenza B virus infection and considerations for clinical management	44
Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development	39
Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection	37
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2	36
Betulinic acid exhibits antiviral effects against dengue virus infection	35
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2	35
Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system	35
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir	34
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo	34
Cinnamic acid inhibits Zika virus by inhibiting RdRp activity	33
A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera	33

A synthetic STING agonist inhibits the replication of human parainfluenza virus 3 and rhinovirus 16 through distinct mechanisms	30
HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals	30
Inhibition of herpes simplex virus 1 by cepharanthine via promoting cellular autophagy through up-regulation of STING/TBK1/P62 pathway	29
The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo	29
Allosteric inhibitors of the main protease of SARS-CoV-2	29
Diketo acids inhibit the cap-snatching endonuclease of several Bunyavirales	29